Life Sciences Talent Needs Scalable RPO

Why Life Sciences Talent Leaders Need a Scalable RPO Model Before the Next Hiring Surge

For two years, life sciences talent teams have run lean. Budgets tightened. Requisitions froze. Many firms cut in-house recruitment to match a slow market. Now, that era is ending. So talent leaders need a plan before it does.

The pipeline is turning faster than talent capacity

Deloitte’s 2026 Life Sciences Outlook Survey found strong leader confidence. In fact, more than 75% of biopharma and medtech executives feel confident in their own financial outlook. As a result, that confidence is now showing up in hiring plans. Nearly half of biopharma leaders, 48%, plan to launch new therapies in 2026. Meanwhile, a further 43% plan to expand into new therapeutic areas.

Deal activity backs this up too. In the first three quarters of 2025, deal value hit $91.9 billion. That is already ahead of the full 2024 total of $61.7 billion. Typically, pipeline growth and deal activity move together. So does talent demand. For teams that spent two years cutting back, this means a real gap just as demand returns.

Specialist skills are getting harder to find

The talent this pipeline needs is not broad talent. In fact, the IQVIA Institute’s Global R&D Trends 2026 report is blunt about this. Competition for talent is fierce, it says. Skills that combine deep science with R&D domain know-how are in high demand.

Deloitte’s data shows where that demand sits. Large molecules, cell and gene therapies, and antibody-drug conjugates are the three areas leaders expect to drive growth. These are narrow talent pools, not broad ones.

For example, think of a hiring manager who needs someone who knows both DNA damage biology and modern ADC manufacture. That person is rare. Worse still, every other firm chasing the same pipeline goal is hunting for them too.

This is not only a science problem either. Deloitte notes that AI is now central to how leading firms plan to run R&D and commercial operations in 2026. So the strongest candidates increasingly need two things at once: deep domain science and comfort working alongside data and automation tools. Internal talent teams built for a slower market rarely have the sourcing reach to find both traits in one person, at speed, across multiple open roles at the same time.

Why RPO and MSP give talent teams room to move

This is where the maths gets hard. Many internal talent teams were cut during the slow years. Now they face rising demand in the toughest roles the market has. Rehiring recruiters takes time. Training them takes longer still. By then, pipeline goals may have shifted again.

An RPO or MSP model solves this a different way. Talent leaders do not need to rebuild fixed headcount to match a demand curve no one can predict. Instead, they gain recruitment capacity that scales with each wave of roles. A total talent solution goes further still. It blends permanent hires with contract and interim staff. As a result, clinical and R&D teams can flex as trial phases shift.

This model also guards against the other risk. Deloitte’s regional data shows growth may land unevenly in 2026. If that happens, talent leaders avoid a fixed cost base built for a surge that never fully lands. So capacity flexes down just as easily as it flexes up.

What a scalable model looks like in practice

In practice, a strong RPO model starts with market mapping, not job postings. Before roles even open, specialist recruiters build live maps of where ADC, cell and gene therapy, and DDR talent actually sits. This means a search can start on day one, not week six.

An MSP model works alongside this for contract and interim needs. As trial phases move, contractor demand moves with them. So a single point of contact manages that entire contingent layer, rather than five separate agencies competing for the same short list.

A true total talent solution links both together. One team, one view of demand, and one set of reporting lines back to talent acquisition and procurement. As a result, heads of talent get a single lever to pull, not three disconnected ones. That single lever matters most when demand shifts quickly, which is exactly what the current data points to.

So the real question for heads of talent, HR directors and procurement leads is simple. It is not whether pipeline-driven hiring will return. Deloitte and IQVIA both say it already has. Instead, the real question is this: will internal capacity be ready in time? If not, the search for ADC and gene therapy specialists starts from zero, at the exact moment competitors are already six months into theirs.

Timing matters here more than most workforce decisions. Building an RPO or MSP relationship takes time to set up properly, from market mapping to process design to team onboarding. Firms that wait until requisitions spike are already behind. Firms that build the relationship now, while demand is still rising rather than peaking, get the benefit of a partner who already understands their pipeline before the busiest quarter of the search begins.

By Dave Watson, VP Talent Solutions, Skills Alliance Enterprise